SHANXI ZHENDONG PHARMACEUTICAL CO.,LTD (300158.SZ)

Wednesday

4:06 AM

Thesis: The company's recent struggles with operating cash flow and increasing competition in the generic drug market have raised concerns among investors…

Revenue Outlook

Metric	FY2024	FY2025
Revenue	$3.0B	$2.8B
Rev. Growth	-18.1%	-6.8%
EPS	$-1.30	$-0.30
EPS Growth	-2937%	+76.9%
P/E	—	—

What Moves the Stock

1Regulatory approvals for new drug formulations
2Market share changes in the generic drug segment
3Pricing strategies in response to competitive pressures
4Partnerships or collaborations with larger pharmaceutical firms
5Generic pharmaceuticals - 60%
6Specialty pharmaceuticals - 30%
7Traditional Chinese medicine - 10%
8Growing demand for traditional Chinese medicine

FY2025 Snapshot

Revenue: $2.8B
Rev. Growth: -6.8%
Gross Margin: 46.9%
Op. Margin: -11.0%
Net Margin: -10.9%
Net Income: $-301M
NI Growth: +77.3%
EPS: $-0.30
1Y Return: +9.5%

300158.SZ Chart

My Notes

"Management has indicated that 'while we see opportunities in traditional medicine, the competitive landscape for generics is becoming increasingly challenging.'"
Moat: The company has a moderate moat due to its focus on traditional Chinese medicine and established distribution channels.
value - Investors may be drawn to the stock due to its low valuation metrics despite current operational challenges.
Low - The company has minimal debt exposure (Debt/Equity of 0.08), so rising interest rates do not significantly affect financing costs.
Watch on earnings: Regulatory approval timelines for new drugs, Market share in the generic pharmaceuticals sector, Gross margin trends.

One Sentence Summary:

Shanxi Zhendong Pharmaceutical Co.,Ltd: the story is balanced — regulatory approvals for new drug formulations.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance